Cat. #161581
PC-3 D12 cell line
Cat. #: 161581
Availability: 8-10 weeks
Organism: Human
Tissue: Pancreas
Disease: Cancer
Model: Mutant
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: William G Watson
Institute: University College Dublin
Primary Citation: O'Neill et al. Mol Cancer. 2011 Oct 7;10:126. PMID: 21982118
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: PC-3 D12 cell line
- Alternate name: PC-3 Docetaxel resistant cell line
- Cancer: Pancreatic cancer
- Cancers detailed: Pancreatic cancer
- Research fields: Cancer
- Organism: Human
- Tissue: Pancreas
- Disease: Cancer
- Growth properties: Suspension
- Model: Mutant
- Crispr: No
- Products or characteristics of interest: Docetaxel resistant cell line
- Description: Docetaxel resistant sub-lines were generated in the androgen-independent (PC-3, DU-145) and sensitive (22RV1) cell lines. One of the main mechanisms of resistance to Docetaxel is the over expression of P-gp which would reduce intracellular concentrations of the drug through increased efflux. Chemoresistant PC-3 cells do not over express P-gp. We demonstrated that the resistance in the PC-3 sublines was independent of P-gp over expression as there were no detectable levels and no effects of the P-gp inhibitor Elacridar on their resistance
- Application: Mechanisms of resistance to Docetaxe in pancreatic cancer cells
- Production details: PC-3 resistant sub-lines were generated by initially treating with Docetaxel (Sigma) at 4 nM and 8 nM (suspended in dimethyl sulfoxide (DMSO) (Fluke)) in 75 cm2 flasks for 48 hours. After treatment, the surviving cells were re-seeded into new flasks and allowed to recover for 2-3 weeks. After 5 (at 8 nM) and 7 (at 4 nM) treatments, the dose of docetaxel was increased from 4 nM and 8 nM to 8 nM and 12 nM respectively. The cells underwent a total of 18 treatment cycles at 8 nM and 12 treatment ...
Applications
- Application: Mechanisms of resistance to Docetaxe in pancreatic cancer cells
Handling
- Format: Frozen
- Growth medium: RPMI-1640 medium supplemented with 10% Fetal Bovine Serum (FBS), 50 U/ml penicillin/50 ?g/ml streptomycin and 2 mM L-glutamine
- Shipping conditions: Dry Ice
- Storage conditions: Liquid Nitrogen
References
- O'Neill et al. Mol Cancer. 2011 Oct 7
- 10:126. PMID: 21982118
